One of its sub-studies, the ADAPT HR+/HER-2- (ClinicalTrials.gov identifier: NCT01779206), is designed to recruit 4000 HR+, HER-2 negative BC women between 18 and 75 years of age with any tumour size (T1-T4, except inflammatory BC) and nodal status (N0-N3). Here, ERBB2 is linked to breast cancer.